These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34445268)

  • 1. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
    Huang YL; Chen PR; Lai YJ; Hsu HH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.
    Marsh KM; Schipper D; Ferng AS; Johnson K; Fisher J; Knapp S; Dicken D; Khalpey Z
    Lung; 2017 Aug; 195(4):425-430. PubMed ID: 28577037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
    Kristof AS; You Z; Han YS; Giaid A
    Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
    Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
    Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.
    Al Mahi N; Zhang EY; Sherman S; Yu JJ; Medvedovic M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis.
    Merrilees MJ; Hankin EJ; Black JL; Beaumont B
    J Pathol; 2004 Jun; 203(2):653-60. PubMed ID: 15141380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
    Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
    Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
    Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
    Goncharova EA; Krymskaya VP
    J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
    Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
    Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
    Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
    J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.